artnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016

Similar documents
artnet AG Quarterly Interim Statement for the First Quarter of 2017 artnet AG Quarterly Interim Statement for the First Quarter of 2017

Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017

Boiron Group confirms its forecasts for year 2008 : sales increase and growth in current operating income.

Coloplast A/S. Investor presentation 1H 2005/06

Summary of Results for the First Half of FY2015/3

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011

Telekom Austria Group Results for the 1st Quarter May 27, 2003

THIRD QUARTER REPORT 2011 (UNAUDITED)

Singapore Exchange Limited 1Q FY2009 Financial Results

RULES OF CONDUCT OF INSIDERS RESPECTING

FY2016 1H Results. Cookpad Inc.

Universal Biosensors, Inc.

For personal use only

INVESTOR PRESENTATION

For personal use only

Endesa 1Q 2017 Results 09/05/2017

Interim Report 1 January September 2017

Consolidated: Financial Summary

Russia Cardiac Assist Devices Market Outlook to 2021

Zacks Small-Cap Research

MDxHealth. Strong outlook for Research Note.

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

FY2007 Consolidated Financial Overview

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009

Putting ALK on the right growth trajectory

MANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.

MDxHealth. Excellent Buy Opportunity. Research Note.

Small-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK

Forward-Looking Statements

ThromboGenics Business Update H1 2018

METVIX PDT ON THE MARKET IN GERMANY AND UK

Acquisition of BP s Interests in Bruce, Keith and Rhum Fields in the North Sea Frequently Asked Questions

Valneva Reports Strong Revenue Growth and Positive EBITDA in H1 Confirming the Company s Trend towards EBITDA Break-even

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

These Rules of Membership apply in respect of all Products purchased by a Member from Sigma (and any Program Partner) on or after 1 February 2017.

Small-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183)

Introductory Presentation

Slide 1. Investor presentation. London 5 February 2019

Investor Presentation June 2012 NASDAQ: CEMI

Friends raises funds, offers expertise, collects donations, and provides volunteer support to help:

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011

Small-Cap Research. Celator Pharma (CPXX-NASDAQ)

ASX Investor Presentation

MDxHealth. Acceleration of payor coverage ConfirmMDx. Research Note.

Small-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK

Q Investor Kit JANUARY-MARCH 2014

Genomic Health. Kim Popovits, Chairman, CEO and President

biomérieux - First-Half 2009 Business Review

Interim report Second quarter 2017 and subsequent events (Unaudited)

Presentation First quarter 2006

A world leader in allergy immunotherapy

Investor Presentation

Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors

Q Investor Kit January December 2014

1Q2017 法人說明會 Jun. 9, 2017

VolitionRx Announces First Quarter 2016 Financial Results and Business Update

NORTH AMERICAN DERMATOLOGY. M&A Activity and Valuation Trends Q Robert Ullman Managing Director

Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

INVESTOR PRESENTATION

ABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210

China Insulin Industry Report, Jan. 2011

HILLENBRAND INDUSTRIES INC

SWEDISH MATCH INVESTOR KIT Q4 2016

Report for the fourth quarter of 2016 and subsequent events (Un-audited)

Summary Statement of Financial Position (consolidated)

Q Investor Kit JANUARY-MARCH 2013

ALK-Abelló A/S. Click View,Header and Footer to change this text to filename and department name

WntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE

Company overview. Highlights for the 1 st quarter 2018 (January-March)

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS

H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review

Business Results. for the First Quarter of FY2016/3. August 4, 2015 (Tue.) NH Foods Ltd.

Disabled and Alone/Life Services for the Handicapped, Inc.

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

Oncolytics Biotech Inc. Announces Third Quarter 2010 Results

Diagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015

This is a licensed product of Ken Research and should not be copied

INTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical

MDxHealth. AssureMDx leaves competition behind. Research Note.

Zealand Pharma A/S Interim report for Q (un-audited)

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)

Investor Presentation

PVD (PVDrilling) Company Visit October 2011

BALCHEM CORPORATION. Q Investor Relations Presentation

Immunity for Life TM. Third Quarter CEO Lars Viksmoen CFO Finn Samuelsen. 31 October 2007

MINUTES OF THE ANNUAL SOLVAY S.A. SHAREHOLDERS MEETING On Tuesday, May 10, 2016 at 10:30 a.m.

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016

Michael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation

Transcription:

Quarterly Interim Statement for the First Quarter of 2016

Quarterly Interim Statement for the First Quarter of 2016 for Table of Contents General Information and Business Activities Economic Development of the Group Development of Segments Financial Status Opportunities and Risks Outlook artnet Authorities, Addresses, Investor Relations, artnet Stock (+36%). Revenue from the Price Database remained stable, while revenue from the Gallery Network fell 3% and the number of gallery memberships decreased, as compared to the same period last year. Due to targeted sales efforts, the number of gallery memberships increased in the first quarter of 2016, as compared to December 31, 2015. Revenue for artnet Auctions increased by 6% as compared to the first quarter of 2015. Gross profit from sales increased thanks to higher revenue and constant cost of sales (-1%) by 11% to 3.23 million USD, as compared to the first quarter of 2015. Operating expenses also decreased, as compared to the same General Information and Business Activities is a publicly traded corporation headquartered in Berlin, Germany. was incorporated under the laws of Germany in 1998. The address of its registered office is Oranienstraße 164, 10969 Berlin, Germany. holds 100% of the shares in ( Artnet Corp. ), which is located in New York, NY, USA. Artnet Corp. holds 100% of the shares in artnet UK Ltd. and artnet France Sarl. The Group s goal is to provide art collectors, galleries, publishers, auction houses, and art enthusiasts with a comprehensive suite of products that allows users to buy, sell, and research art online. The Price Database contains over 10 million auction records, allowing for in-depth art market research. Users can find artworks that are currently available for sale in the Gallery Network, Auction House Partnerships, or on artnet Auctions, an online transaction platform. artnet News, the 24-hour newswire, informs users about the events, trends, and people shaping the global art market. Economic Development of the Group Compared to the same period last year, artnet increased its revenue in the first quarter of 2016 by 291k USD (+6%) to 4.85 million USD, largely due to higher advertising revenue quarter in the previous year, mainly due to lower expenses for selling and marketing, as well as lower costs for product development. Because of higher revenues and lower expenses, the consolidated earnings increased sharply in what is typically a weak quarter, from -206k USD in the first quarter of 2015 to 287k USD in the first quarter of 2016. Development of Segments Following the general development of the Group as described above, the Contribution Margin II increased for all segments, as compared to the first quarter of 2015. The Contribution Margin II for the Galleries and Price Database segments increased slightly by 6% and 5%, respectively. Due to the large growth in advertising revenue, the Contribution Margin II for the artnet News segment increased by 68%, but remained negative. Higher revenue and lower expenses for product development and marketing allowed the artnet Auctions segment to turn a profit for the first time. Financial Status The financial status of the Group has not changed since the publication of the 2015 Annual Report. While artnet continued to reduce its liabilities mainly the accounts payable and other liabilities even further, the Group s operating cash flow was positive. Due to the redemption of a loan, the reduction of leasing liabilities, and investments made, cash

and cash equivalents increased only slightly as compared to December 31, 2015, even though artnet generated a positive consolidated net income. Opportunities and Risks Since the 2015 Annual Report was published on April 8, 2016, no significant events occurred that may affect the evaluation of future risks and opportunities for the Group. As described in the 2015 Annual Report, the going concern assumption for the Group is endangered by liquidity risks. Damages of 0.8 million EUR could be required on short notice, for the alleged copyright infringement of a French photographer, as determined by the French Court of Appeal. In March 2016, the French Court of Cassation decided in a pre-trial ruling to dismiss artnet s appeal against the judgment of the Court of Appeal, in favor of the motion of the French photographer based on procedural aspects of the case. Aside from all legal remedies, artnet continues its efforts to achieve a settlement with the photographer. artnet does not believe a full payment of damages will be required in 2016. Outlook According to the outlook published in the 2015 Annual Report, artnet is poised to continue its leadership position in a competitive market. Management expects the momentum of rising revenues, coupled with a moderate increase in expenses, to continue, and therefore do not alter its prognoses for the development of the segments in 2016, as made in the annual report 2015. Berlin, April 19, 2016 Jacob Pabst CEO,

Supervisory Board John Hushon, Chairman Hans Neuendorf, Deputy Chairman Piroschka Dossi Management Board artnet France sarl artnet UK Ltd. Addresses Investor Relations You can find information for investors and the annual financial statements at artnet.com/investor-relations. If you have further queries, please send an email to ir@artnet.com, or send your inquiry by mail to one of our offices. German Securities Code Number The common stock of is traded on the Prime Standard of the Frankfurt Stock Exchange under the symbol ART. You can find notices of relevant company developments at artnet.com/investor-relations. Wertpapier-Kenn-Nummer Oranienstraße 164 10969 Berlin info@artnet.de T: +49 (0)30 209 178-0 F: +49 (0)30 209 178-29 [WKN] ISIN A1K037 DE000A1K0375 233 Broadway, 26th Floor New York, NY 10279 USA info@artnet.com T: +1-212-497-9700 F: +1-212-497-9707 artnet UK Ltd. Morrell House 98 Curtain Road London EC2A 3AF United Kingdom info@artnet.co.uk T: +44 (0)20 7729 0824 F: +44 (0)20 7033 9077 Concept and Production 2016, Berlin